Indegene Limited (BSE: 544172, NSE: INDGN) has been named a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 by Everest Group, a leading global research and consulting firm. This recognition underscores Indegene's expertise in providing AI and Analytics solutions across life sciences commercial functions.

Key Highlights

• Indegene's AI and Analytics capabilities acknowledged across life sciences commercial functions
• Recognition for embedding Generative AI and Agentic AI capabilities in solutions portfolio
• Commendation for combining AI and Analytics with domain knowledge in specialty care, oncology, and rare diseases
• Evaluation based on vision, capabilities, and market impact among 30 service providers

Everest Group's Assessment

Everest Group highlighted Indegene's unique ability to combine AI and Analytics capabilities with deep domain knowledge. This combination allows Indegene to deliver contextualized commercial solutions across various therapy areas, including specialty care, oncology, and rare diseases.

Durga Ambati, Practice Director at Everest Group, stated, "Indegene's broad portfolio of solutions within its NEXT platform, as well as its continued investments in embedding GenAI and Agentic AI across its capabilities, are well-complemented by its diverse therapeutic knowledge and strong market-facing assets."

Indegene's AI Strategy

Indegene's unified, enterprise-wide AI approach embeds production-ready solutions across commercial operations. This strategy aims to help life sciences companies achieve significant operational efficiencies and productivity gains, accelerating their journey towards being future-ready.

Vivek Ghai, EVP-Enterprise Commercial Solutions at Indegene, commented, "Our focus is on helping clients scale AI responsibly - prioritizing use cases that drive measurable outcomes, integrating seamlessly with enterprise ecosystems, and delivering solutions that are not just innovative, but production-ready from day one."

Company Profile

Indegene Limited is a digital-first, life sciences commercialization company that serves the world's top 20 biopharma companies and many emerging biotech firms. With around 5,000 employees worldwide, Indegene operates through 9 operations hubs and 19 offices across North America, Europe, and Asia.

The company combines healthcare expertise with a digital-first approach to help pharma, biotech, and medical device companies commercialize their products effectively and efficiently throughout their lifecycle.

This latest recognition by Everest Group further solidifies Indegene's position as a trusted transformation partner for life sciences organizations in the rapidly evolving landscape of AI and analytics-driven commercialization strategies.

Indegene Limited has announced a series of important corporate events, including a board meeting and an earnings call, as the company prepares to disclose its financial results for the first quarter of the fiscal year 2026.

Board Meeting Scheduled

The Board of Directors of Indegene Limited is set to convene on Thursday, July 31, 2025. The meeting agenda includes two key items:

1. Review of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, along with the limited review report from the auditors.
2. Approval of allotments under the ESOP Scheme 2020.

Trading Window Closure

In compliance with SEBI regulations, Indegene has closed its trading window for company securities. The closure began on July 1, 2025, and will remain in effect until 48 hours after the declaration of the quarterly financial results. This measure is designed to prevent insider trading and ensure fair market practices.

Earnings Conference Call

Following the board meeting, Indegene has scheduled an earnings conference call for Friday, August 1, 2025, at 9:00 AM IST. The call will provide an opportunity for investors and analysts to interact with the senior management regarding the Q1 FY26 earnings. Key speakers on the call will include:

• Manish Gupta, Chairman and Chief Executive Officer
• Suhas Prabhu, Chief Financial Officer

Interested parties can access the call through the provided universal access numbers or register in advance using the DiamondPass registration option.

Investor Relations

These announcements underscore Indegene's commitment to transparency and timely communication with its stakeholders. The upcoming board meeting and earnings call will offer valuable insights into the company's performance for the first quarter of the fiscal year 2026.

Investors and market watchers are advised to mark their calendars for these important dates as they await Indegene's financial results and future outlook.